Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)
Background Abemaciclib plus endocrine therapy improves outcomes in high-risk hormone receptor-positive, HER2-negative early breast cancer (EBC) in monarchE, but real-world tolerability, dose modification, and treatment persistence in routine UK practice remain incompletely characterised. Patients and methods A retrospe...